TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Essential Oils on Anxiety of Patients Suffering From Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult suffering from cancer at a metastatic stage~* Life expectancy \> 15 days, assessed by investigator~* Hospitalized at the Chevrel unit from Centre Eugène Marquis, palliative unit care, for more than 15 days~* Regular anxiolytic treatment or imperative need to introduce anxiolytic treatment (assessed by investigator) within 48 hours following his hospitalization entry~* \> 18 years~Exclusion Criteria:~* Patient already recruited in a therapeutic trial~* Patient not covered by a social security system~* Pregnant or likely pregnant patient, breastfeeding patient~* Allergy to any component of essential oils mixture and vegetable oils : bitter orange petitgrain, fine lavender, ylang-ylang, macadamia~* Minors, people deprived of their liberty or protected people,~* Impaired cognitive functions making impossible to obtain informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Essential oils then oil massages (Type: EXPERIMENTAL): Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
- Oil then essential oils massages (Type: EXPERIMENTAL): Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active Duty Service Members with Pseudofolliculitis Barbae~Exclusion Criteria:~* Previous treatment with laser hair removal in the previous 12 months, Currently pregnant, seeking pregnancy, or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Paired(right and left neck) comparison group eflornithine (Type: ACTIVE_COMPARATOR): randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.
- Paired(right and left neck) comparison group placebo (Type: PLACEBO_COMPARATOR): randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: EIMD Mechanisms Causing Force Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age range of 18-35 years of age~* males and females who do not have a history of orthopedic injuries of the hip knee, and/or leg~* Participants must be engaged in some form of physical activity on at least 3 days each week~Exclusion Criteria:~* An answer of yes to any of the seven questions on the physical activity readiness questionnaire (PAR-Q)~* Average daily consumption of more than 40mg of caffeine per day as determined by the 2 week caffeine recall questionnaire~* Use of any type of prescription psychiatric or prescription or over-the-counter pain medication~* An answer of yes to questions 1,2,8, and 15-22 on the rhabdomyolysis screening questionnaire~* An answer of yes on questions 3,4,6,7,8, 11,12, and 13 if the follow up information indicates any type of medication, drug, supplement, illness, and/or dietary need that could affect pain sensitivity or the risk of dehydration. Determinations will be made on a participant-by-participant basis depending on the answers provided~* An answer of yes on question 24 indicating a previous adverse reaction to caffeine consumption~* Resting systolic blood pressure \>140 mmHg and/or resting diastolic blood pressure \>90 mmHg~* Pregnancy or suspicion of pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Caffeine Pill (Type: ACTIVE_COMPARATOR): The caffeine will be administered.
- Placebo/Flour Pill (Type: PLACEBO_COMPARATOR): The flour will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Patients with BN:~* Meets DSM-IV criteria for BN~* BN duration of more than 1 year~* Self-induces vomiting~* Weighs between 80 and 120% of ideal body weight~Exclusion Criteria for Patients with BN:~* Significant medical illness~* Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as defined by DSM-IV-TR criteria~* Current DSM-IV-TR diagnosis of organic mental disorder, factitious disorder, or malingering~* History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with the study procedures~* At risk for suicide, as defined by the expression of an imminent plan or attempt within the 6 months prior to study entry~* Currently taking psychotropic medications or medications that affect gastrointestinal function~* Moderate to severe depression, as defined by a score of greater than 28 on the Hamilton Depression Rating Scale~* Drug or alcohol abuse within the 3 months prior to study entry~* Pregnant, planning to become pregnant, or lactating~* Body mass index (BMI) of less than 18 (underweight)~Inclusion Criteria for Normal Weight Controls:~* No current or past psychiatric history~* No history of binge eating or vomiting~* 80-120% of ideal body weight~Exclusion Criteria for Normal Weight Controls:~* Significant medical illness~* Current psychotropic medications and current medications that affect GI function~* Drug or alcohol abuse in last 3 months~* Pregnancy, planning to become pregnant or laction

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cholecystokinin (Type: EXPERIMENTAL): Participants will receive intravenous saline plus cholescystokinin.
- Saline (Type: PLACEBO_COMPARATOR): Participants will receive intravenous saline only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Dynamic Dressing in the Management of Unoperated Hallux Valgus (DYNHALLUX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hallux valgus on at least one foot theoretically requiring surgical management within 12 months~* reducible hallux valgus~* wearing custom-made orthopedic insoles made by a biomechanical podiatrist - SHORE ≥ 65 - for at least 2 months at the time of inclusion~* beneficiary of a social security scheme~* informed of the study and signed informed consent form~Exclusion Criteria:~* History of hallux valgus correction surgery on the affected foot~* History of traumatic lesion of the M1-P1 metatarsophalangeal joint of the affected foot~* Skin pathology limiting or contraindicating the possibility of dressings according to the judgment of the investigator (eg dyshidrotic eczema, psoriasis or other problematic skin damage located in the foot)~* Acute bursitis~* Clinical and / or radiological stage 1 or more osteoarthritis according to the criteria of Kellgren and Lawrence~* Non-stabilized diabetes and / or diabetes with micro / macrovascular complications~* Patients with neuropathy~* History of gout~* History of rheumatic pathology~* Obliterating arteriopathy of the lower limbs of stage II or more according to the classification of Leriche and Fontaine~* Pregnant woman~* Patients under tutorship or curatorship~* Patients under legal protection~* Patients who do not understand French

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: NO_INTERVENTION): wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
- Interventional arm (Type: EXPERIMENTAL): wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medically confirmed diagnosis of persistent asthma~* Able to demonstrate reversibility of at least 12% with albuterol inhalation~* Use of short-acting b-2 agonists for rescue \>= 5 times within 2 weeks prior~* Able to produce an FEV1 between 45 and 85% of predicted~* Willing to perform study procedures for about 14 weeks.~Exclusion Criteria:~* Use of inhaled corticosteroids within 4 weeks~* Use of oral/parenteral corticosteroids within 8 weeks~* Use of long-acting beta-2 agonists or montelukast within 2 weeks~* History of life-threatening asthma attack within 3 months~* Female of child bearing potential.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): sham comparator 3(100 mg) tablets once daily for 12 weeks
- 001 (Type: EXPERIMENTAL): JNJ-18054478 3(100 mg) tablets once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females older than 18 years of age~* Is clinically indicated for contrast-enhanced MDCT of the pancreas~* Scheduled for MDCT and therapeutic or diagnostic ERCP for the assessment of chronic pancreatitis~* Has been fully informed and has personally signed and dated the Written Informed Consent and Health Insurance Portability Accountability Act (HIPAA) provisions~* Is a male, or is a female not of childbearing potential, or is a female of childbearing potential who is using effective contraception and has a negative urine pregnancy test on the same day, but prior to, study drug administration~* Is able and willing to complete all study procedures specified in the protocol~Exclusion Criteria:~* Has no clear written indication for contrast enhanced MDCT of the pancreas~* Has a history of hypersensitivity to iodine-containing compounds~* Has congestive cardiac failure (class III-IV in accordance with the classification of the New York Heart Association \[NYHA\])~* Presence of a pancreatic stent~* Is unable to comply with the study requirements including follow-up~* History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease which, in the opinion of the investigator, precludes study participation~* History of sensitivity to any of the ingredients in the study drug~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug + MDCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (18+ years) recipients of kidney or kidney/pancreas transplants~* Willing to sign an IRB (institutional review board)-approved consent and to comply with study requirements~* DSA (donor specific antibodies) detected by SAB (single antigen beads) screening with MFI ≥ 2000~* Graft biopsy performed within prior 30 days~* Stable renal function defined by serum creatinine increase ≤ 30% over prior 6 months~* Subacute antibody-mediated rejection on biopsy defined by ptc + g + C4d ≥ 2 by Banff 2013 criteria~Exclusion Criteria:~* Kidney/liver or kidney/heart recipient~* Unwilling/unable to undergo screening biopsy~* HIV (human immunodeficiency virus), HCV (hepatitis-C virus), or HBsAg (hepatitis-B surface antigen) positive~* Active/untreated infection~* Acute cellular rejection with Banff grade 1b, 2a, 2b on initial biopsy requiring rATG (rabbit anti-thymocyte globulin) therapy~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - conversion to Envarsus XR (Type: ACTIVE_COMPARATOR): Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet \[Envarsus\]) with goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
- Arm 2 - plasma exchange and IVIG (Type: ACTIVE_COMPARATOR): Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed invasive breast cancer~* Must have known ER, PR and HER2 status~* Either, Triple Negative Metastatic Breast Cancer or~* Inflammatory Breast Cancer with any ER, PR HER2 status~* Availability of archival tissue specimen suitable for pStat3 testing~* Life expectancy of greater than 3 months~* Measurable disease by RECIST~* At least one prior chemotherapy regimen for treatment of metastatic breast cancer and/or recurrence within 12 months of completion of neoadjuvant/adjuvant chemotherapy or~* For patients with inflammatory breast cancer but no distant metastases, progression through standard neoadjuvant chemotherapy is required~Exclusion Criteria:~* Pregnant or breastfeeding~* Active brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib~* Clinically significant malabsorption syndrome~* Concurrent use of medications/substances that are strong inhibitors of CY3A4~* No uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib-Cohort A (Type: EXPERIMENTAL): Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of \>/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
- Ruxolitinib-Cohort B (Type: EXPERIMENTAL): Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of \>/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Lcr35 / ICU / P. Aeruginosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* more than 18 years old~* length of stay longer than 48h~* with a nasogastric feeding tube~Exclusion Criteria:~* - less than 18 years old~* length of stay \< 48h~* immunosuppression~* absolute neutrophile count \< 500/mm3~* gastro-intestinal bleeding~* contraindicated enteral feeding~* positive P. aeruginosa gastric aspirates or respiratory tract specimens during the first four days after hospital admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Glioblastoma Multiforme (GBM)~* Prior treatment with radiation and one first line systemic therapy (including temozolomide or other chemotherapy, immunotherapy, targeted therapy or combination therapies), followed by measurable and unequivocal evidence of tumor progression or recurrence~* Age ≥ 18 years~* ECOG ≤ 2~* Normal organ and marrow function as defined below:~  * leukocytes ≥3 x 109/L~ * absolute neutrophil count ≥1.5 x 109/L~ * platelets ≥100 x 109/L~ * hemoglobin ≥90 g/L~ * total bilirubin ≤2.5 X institutional upper limit of normal~ * AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal~ * creatinine ≤1.0 X institutional upper limit of normal~Exclusion Criteria:~* Patients with a life expectancy \< 12 weeks~* Patients with a documented history of HIV, active hepatitis B or C infections~* Female patients who are pregnant or lactating~* Patients in whom a proper central line (Portacath-like device) cannot be established~* Patients with a known hypersensitivity to farnesylated dibenzodiazepinone or polysorbate 80~* Patients with uncontrolled hypotension~* Patients with concomitant therapy of therapeutic coumadin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single-Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Hypertrophic cardiomyopathy with symptoms of moderate-to-severe heart failure~* Left ventricular hypertrophy with maximum LV wall thickness ≥ 15 mm~* Left ventricular ejection fraction ≥ 50%~* Able to perform exercise testing but unable to exceed 75% of the predicted age-adjusted maximum level~Key Exclusion Criteria:~* CYP2D6 Poor Metabolizer (PM) status~* History of a known chronic liver disease~* ALT, AST, alkaline phosphatase, or LDH \> 1.5 x upper limit of normal~* Total Bilirubin \> 2.0 x upper limit of normal~* Severe LV outflow obstruction~* Asymptomatic patients or cardiomyopathy-related criteria as per protocol~* QT interval related criteria as per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perhexiline (Type: EXPERIMENTAL): Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy